Question to the Department of Health and Social Care:

To ask His Majesty's Government what are the clinical criteria for success for the trial of tirzepatide in Greater Manchester, announced on 15 October.

The SURMOUNT-REAL clinical trial of tirzepatide, announced on 15 October 2024, is being developed between Health Innovation Manchester, The University of Manchester, and Eli Lilly and Company, with further details about the study to be published by these organisations at a later date, following on from relevant approvals.

The study will evaluate the real-world effectiveness of tirzepatide in weight loss, diabetes prevention, and the prevention of obesity-related complications for people living with obesity. Additionally, data will be collected on healthcare resource utilisation, health-related quality of life, and changes in participants’ employment status, including sick days from work.

The evidence generated will seek to increase the global evidence base on the long-term impacts of weight loss medicines more broadly, and the placement of the trial is a clear vote of confidence in the United Kingdom from a global healthcare stakeholder, working with our brilliant and regionally diverse life sciences sector to improve understanding of a priority healthcare field.

This announcement was made as part of a collaboration agreement between Eli Lilly and Company and Government unveiled at the International Investment Summit, as part of an intended £279 million package of investment from Eli Lilly and Company into the UK's innovation and research ecosystem.